Approved asthma biologic antibodies target critical points surrounding the T2 immune response including T2 cytokine signaling (IL-4, IL-5, and IL-13), downstream T2 response (IgE), and upstream T2 initiation [thymic stromal lymphopoietin (TSLP)]. This evidence concerns the gene IL13 and asthma.